- Home
- MUJ vs KROS Comparison
MUJ vs KROS Comparison
Compare MUJ & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- KROS
- Stock Information
- Founded
- MUJ 1998
- KROS 2015
- Country
- MUJ United States
- KROS United States
- Employees
- MUJ N/A
- KROS N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- KROS Health Care
- Exchange
- MUJ Nasdaq
- KROS Nasdaq
- Market Cap
- MUJ 619.6M
- KROS 565.0M
- IPO Year
- MUJ N/A
- KROS 2020
- Fundamental
- Price
- MUJ $11.62
- KROS $15.05
- Analyst Decision
- MUJ
- KROS Buy
- Analyst Count
- MUJ 0
- KROS 14
- Target Price
- MUJ N/A
- KROS $20.56
- AVG Volume (30 Days)
- MUJ 108.0K
- KROS 1.0M
- Earning Date
- MUJ 01-01-0001
- KROS 11-06-2025
- Dividend Yield
- MUJ 4.36%
- KROS N/A
- EPS Growth
- MUJ N/A
- KROS N/A
- EPS
- MUJ N/A
- KROS 0.47
- Revenue
- MUJ N/A
- KROS $232,844,000.00
- Revenue This Year
- MUJ N/A
- KROS $6,657.47
- Revenue Next Year
- MUJ N/A
- KROS N/A
- P/E Ratio
- MUJ N/A
- KROS $32.32
- Revenue Growth
- MUJ N/A
- KROS 85820.30
- 52 Week Low
- MUJ $9.74
- KROS $9.12
- 52 Week High
- MUJ $11.70
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- MUJ 60.05
- KROS 47.21
- Support Level
- MUJ $11.50
- KROS $13.60
- Resistance Level
- MUJ $11.62
- KROS $15.76
- Average True Range (ATR)
- MUJ 0.08
- KROS 0.70
- MACD
- MUJ -0.02
- KROS -0.04
- Stochastic Oscillator
- MUJ 57.14
- KROS 50.35
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund mainly invests in long-term, investment-grade municipal obligations exempt from U.S federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and New Jersey personal income taxes, with remaining maturities of one year or more at the time of investment. The rest of its managed assets can be invested in securities that are rated below investment grade (or similar instruments), or invested directly in securities or synthetically through the use of derivatives.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.